Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2096618 Target Snapshot

Bcr/Abl fusion protein · CHIMERIC PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,039Compounds
310Assays
16Approved Drugs
1,090.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Bcr/Abl fusion protein shows approved-linked disease relevance led by chronic myelogenous leukemia. 5 more disease programs remain visible in the same review block. 9 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P00519. Start with chronic myelogenous leukemia, then reuse UniProt P00519 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with chronic myelogenous leukemia, then reuse UniProt P00519 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 9 linked drugs
Open source guide
Disease program
chronic myelogenous leukemia

Bcr/Abl fusion protein shows approved-linked disease relevance led by chronic myelogenous leukemia. 5 more disease programs remain visible in the same review block. 9 linked drugs remain visible in the same block.

Start review with chronic myelogenous leukemia because it currently carries approved-linked support. Linked drugs include ASCIMINIB HYDROCHLORIDE, BOSUTINIB MONOHYDRATE, DASATINIB ANHYDROUS, IMATINIB MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 9 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Bcr/Abl fusion protein as ChEMBL target CHEMBL2096618, mapped to UniProt P00519. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Bcr/Abl fusion protein
CHIMERIC PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2096618
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P00519
Tyrosine-protein kinase ABL1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Bcr/Abl fusion protein is the right protein anchor across sources, using UniProt P00519 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why chronic myelogenous leukemia is currently framed as approved-linked support. It currently carries 9 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameBcr/Abl fusion protein
Target TypeCHIMERIC PROTEIN
OrganismHomo sapiens
UniProtP00519
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelTyrosine-protein kinase ABL1
UniProt AccessionP00519
Component TypeProtein
Sequence Length1130 aa

Tyrosine-protein kinase ABL1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Bcr/Abl fusion protein, mapped to UniProt P00519. ChEMBL maps the protein component as Tyrosine-protein kinase ABL1. Sequence length is 1130 aa.

Mapped IDP00519
Review nameBcr/Abl fusion protein
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Bcr/Abl fusion protein shows approved-linked disease relevance led by chronic myelogenous leukemia. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
chronic myelogenous leukemia
9 linked drugs · 9 direct · 9 efficacy
Linked drugASCIMINIB HYDROCHLORIDE
Linked drugBOSUTINIB MONOHYDRATE
Linked drugDASATINIB ANHYDROUS
Linked drugIMATINIB MESYLATE
Approved-linked Approved
Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
5 linked drugs · 5 direct · 5 efficacy
Linked drugASCIMINIB HYDROCHLORIDE
Linked drugDASATINIB
Linked drugDASATINIB ANHYDROUS
Linked drugIMATINIB MESYLATE
Approved-linked Approved
myeloid leukemia
5 linked drugs · 5 direct · 5 efficacy
Linked drugBOSUTINIB MONOHYDRATE
Linked drugDASATINIB ANHYDROUS
Linked drugOLVEREMBATINIB
Linked drugPONATINIB HYDROCHLORIDE
Approved-linked Approved
acute lymphoblastic leukemia
4 linked drugs · 4 direct · 4 efficacy
Linked drugDASATINIB ANHYDROUS
Linked drugIMATINIB MESYLATE
Linked drugOLVEREMBATINIB
Linked drugPONATINIB HYDROCHLORIDE
Approved-linked Approved
neoplasm
4 linked drugs · 4 direct · 4 efficacy
Linked drugDASATINIB ANHYDROUS
Linked drugIMATINIB MESYLATE
Linked drugNILOTINIB HYDROCHLORIDE MONOHYDRATE
Linked drugOLVEREMBATINIB
Approved-linked Approved
cancer
3 linked drugs · 3 direct · 3 efficacy
Linked drugDASATINIB ANHYDROUS
Linked drugIMATINIB MESYLATE
Linked drugPONATINIB HYDROCHLORIDE
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with chronic myelogenous leukemia because it currently carries approved-linked support. Linked drugs include ASCIMINIB HYDROCHLORIDE, BOSUTINIB MONOHYDRATE, DASATINIB ANHYDROUS, IMATINIB MESYLATE. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasechronic myelogenous leukemia
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

16
Approved
4
Phase III
6
Phase II
1
Phase I
Assay Mix

Activity Type Distribution

IC50939.0
KI5.0
EC50137.0
KD9.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5416410 10.8 IC50 0.016 Approved
CHEMBL5416410 10.52 Ki 0.03 Approved
CHEMBL3808884 10.4 EC50 0.04 Preclinical
CHEMBL5416410 10.4 EC50 0.04 Approved
CHEMBL1171837 10.3 EC50 0.05 Approved
CHEMBL4208229 9.89 EC50 0.13 Approved
CHEMBL2178270 9.48 IC50 0.33 Preclinical
CHEMBL255863 9.48 IC50 0.33 Approved
CHEMBL2178277 9.44 IC50 0.36 Preclinical
CHEMBL2178271 9.39 IC50 0.41 Preclinical
Distribution

pChEMBL Value Distribution

120
5.0
103
5.5
142
6.0
107
6.5
69
7.0
81
7.5
50
8.0
29
8.5
38
9.0
4
9.5
pChEMBL
Approved Drugs

Approved Drugs

ASCIMINIB
CHEMBL4208229
Approved 2021
Properties Compare Identifier
TIRBANIBULIN
CHEMBL571546
Approved 2020
Properties Compare Identifier
PONATINIB
CHEMBL1171837
Approved 2012
Properties Compare Identifier
BOSUTINIB
CHEMBL288441
Approved 2012
Properties Compare Identifier
NILOTINIB
CHEMBL255863
Approved 2007
Properties Compare Identifier
DASATINIB
CHEMBL5416410
Approved 2006
Properties Compare Identifier
DASATINIB ANHYDROUS
CHEMBL1421
Approved 2006
Properties Compare Identifier
IMATINIB
CHEMBL941
Approved 2001
Properties Compare Identifier
IMATINIB MESYLATE
CHEMBL1642
Approved 2001
Properties Compare Identifier
Assay Landscape

Assay Landscape

310
Total Assays
559
Tested Compounds
3
Assay Types
Binding — 304 assays, 559 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 209 129 6.4
protein format 91 386 6.6
assay format 3 29 5.9
single protein format 1 15 7.2
Functional — 4 assays, 31 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 4 31 5.3
Toxicity — 2 assays, 1 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 2 1 8.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine